R Duverna1, S Y Ablordeppey, N S Lamango. 1. College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida 32307, USA.
Abstract
Polyisoprenylated proteins (PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determined by the two competing reactions. Since PMPMEase and PPMTase may influence both the structural/functional conformations of PPs, a thorough study of these enzymes is essential to our understanding of the structural/functional features of PPs. PMPMEase has been reported under such pseudonyms as human carboxylesterase 1 (hCE1) because of its apparent broad substrate spectrum. The current study aimed to show the complementarity between its active site and the polyisoprenylated substrates that it metabolizes. Kinetics analysis was conducted with N-, S- and O-substituted substrates using porcine liver PMPMEase and docking analysis using Arguslab. Consistent with the biochemical analysis, the S-ethyl analog yielded an AScore binding energy of -11.32 compared to -13.48, -14.88, -16.15, and -16.81 kcal/mol for S-prenyl (C-5), S-trans-geranyl (C-10), S-trans,trans-farnesyl (C-15) and S-all trans-geranylgeranyl (C-20), respectively. The all trans-geranylgeranyl moiety provides the optimal size for active site interactions. The data reveal that the trans,trans-farnesyl and all trans-geranylgeranyl groups, which are reminiscent of endogenous PPs modifications, have the highest affinity for PMPMEase. Since PPs such as monomeric G-proteins are oncogenic, PMPMEase may be viewed as a viable target for anticancer drug development. The analyses reveal the important structural elements for the design of specific PMPMEase inhibitors to serve in the modulation of oncogenic PPs activities. The results also show that hCE1's repertoire of substrates extends beyond xenobiotics to include PPs as its endogenous substrates.
Polyisoprenylated proteins (class="Chemical">PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl n class="Chemical">esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determined by the two competing reactions. Since PMPMEase and PPMTase may influence both the structural/functional conformations of PPs, a thorough study of these enzymes is essential to our understanding of the structural/functional features of PPs. PMPMEase has been reported under such pseudonyms as humancarboxylesterase 1 (hCE1) because of its apparent broad substrate spectrum. The current study aimed to show the complementarity between its active site and the polyisoprenylated substrates that it metabolizes. Kinetics analysis was conducted with N-, S- and O-substituted substrates using porcine liver PMPMEase and docking analysis using Arguslab. Consistent with the biochemical analysis, the S-ethyl analog yielded an AScore binding energy of -11.32 compared to -13.48, -14.88, -16.15, and -16.81 kcal/mol for S-prenyl (C-5), S-trans-geranyl (C-10), S-trans,trans-farnesyl (C-15) and S-all trans-geranylgeranyl (C-20), respectively. The all trans-geranylgeranyl moiety provides the optimal size for active site interactions. The data reveal that the trans,trans-farnesyl and all trans-geranylgeranyl groups, which are reminiscent of endogenous PPs modifications, have the highest affinity for PMPMEase. Since PPs such as monomeric G-proteins are oncogenic, PMPMEase may be viewed as a viable target for anticancer drug development. The analyses reveal the important structural elements for the design of specific PMPMEase inhibitors to serve in the modulation of oncogenic PPs activities. The results also show that hCE1's repertoire of substrates extends beyond xenobiotics to include PPs as its endogenous substrates.
Authors: Vi K Chiu; Joseph Silletti; Victoria Dinsell; Heidi Wiener; Kristina Loukeris; Guoming Ou; Mark R Philips; Michael H Pillinger Journal: J Biol Chem Date: 2003-12-02 Impact factor: 5.157
Authors: Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou Journal: Nat Rev Drug Discov Date: 2007-07 Impact factor: 84.694
Authors: Christopher D Fleming; Sompop Bencharit; Carol C Edwards; Janice L Hyatt; Lyudmila Tsurkan; Feng Bai; Charles Fraga; Christopher L Morton; Escher L Howard-Williams; Philip M Potter; Matthew R Redinbo Journal: J Mol Biol Date: 2005-09-09 Impact factor: 5.469
Authors: Sompop Bencharit; Christopher L Morton; Escher L Howard-Williams; Mary K Danks; Philip M Potter; Matthew R Redinbo Journal: Nat Struct Biol Date: 2002-05
Authors: Byron J Aguilar; Augustine T Nkembo; Randolph Duverna; Rosemary A Poku; Felix Amissah; Seth Y Ablordeppey; Nazarius S Lamango Journal: Eur J Med Chem Date: 2014-05-09 Impact factor: 6.514
Authors: Augustine T Nkembo; Olufisayo Salako; Rosemary A Poku; Felix Amissah; Elizabeth Ntantie; Hernan Flores-Rozas; Nazarius S Lamango Journal: Am J Cancer Res Date: 2016-11-01 Impact factor: 6.166
Authors: Jose M Otero; Manos A Papadakis; D B R K Gupta Udatha; Jens Nielsen; Gianni Panagiotou Journal: PLoS One Date: 2010-10-25 Impact factor: 3.240
Authors: Felix Amissah; Randolph Duverna; Byron J Aguilar; Rosemary A Poku; Nazarius S Lamango Journal: Biomed Res Int Date: 2013-07-01 Impact factor: 3.411